众生药业(002317) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥665,343,383.77, representing an increase of 8.45% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥46,496,210.61, a significant increase of 79.08% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥79,309,984.60, which decreased by 11.54% compared to the same period last year[6]. - The company reported a year-to-date revenue of ¥1,991,202,038.72, which is a 9.19% increase year-on-year[14]. - The company’s net profit for the year-to-date period was ¥248,731,479.51, reflecting a decrease of 20.73% compared to the same period last year[14]. - Total operating revenue for the current period reached ¥1,991,202,038.72, an increase of 9.2% compared to ¥1,823,582,996.89 in the previous period[37]. - Net profit for the current period was ¥246,324,247.33, a decrease of 19.8% from ¥307,197,888.72 in the same period last year[40]. Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥5,811,585,037.95, reflecting an increase of 18.56% from the end of the previous year[6]. - The equity attributable to shareholders at the end of Q3 2022 was ¥3,631,183,288.65, up by 4.47% from the end of the previous year[6]. - The company's total liabilities as of September 30, 2022, amounted to CNY 1,215,961,292.29, compared to CNY 524,197,608.58 at the beginning of the year, marking an increase of about 132.2%[33]. - The company's total liabilities increased to ¥2,119,650,597.21 from ¥1,363,840,852.63, representing a growth of 55.5%[36]. Cash Flow - The cash flow from operating activities for the year-to-date period was ¥139,886,612.94, showing a decrease of 56.55% year-on-year[6]. - The net cash flow from operating activities decreased by 56.55% to approximately CNY 139.89 million, primarily due to reduced cash inflows from operating activities[18]. - Cash flow from operating activities was ¥1,646,897,464.68, down from ¥1,810,933,745.63, showing a decrease of 9.0%[43]. - Cash inflow from other operating activities was ¥81,089,738.48, significantly higher than ¥49,112,805.62 in the previous period[46]. Investments and Expenses - Research and development expenses were ¥88,566,717.23, slightly up from ¥87,165,221.92, indicating a focus on innovation[40]. - Financial expenses surged by 1,892.07% to approximately CNY 60.45 million, mainly due to increased interest on financial liabilities and discounted notes[18]. - The company reported a financial expense of ¥60,446,456.11, significantly higher than ¥3,034,353.30 in the previous period, primarily due to increased interest expenses[40]. Shareholder Information - The company’s total number of ordinary shareholders reached 49,514, with the top two shareholders, Zhang Yuchong and Zhang Yuli, each holding 11.37% of shares[19]. - The company plans to raise a total of up to CNY 678.80 million through a private placement of A-shares, not exceeding 15% of the total share capital prior to the issuance, which amounts to 122,169,161 shares[24]. - The company has received the acceptance notice from the China Securities Regulatory Commission regarding its application for the private placement of shares[24]. Inventory and Receivables - Accounts receivable due within one year increased by 83.94% to approximately CNY 549.83 million, influenced by a reduction in large time deposits classified as current assets[15]. - The company’s inventory stock decreased by 46.99% to approximately CNY 80.35 million due to the implementation of equity incentives[15]. - The company’s inventory as of September 30, 2022, was CNY 449,515,933.12, showing a slight decrease from CNY 452,198,760.24 at the beginning of the year[30]. Other Financial Metrics - The basic earnings per share for Q3 2022 was ¥0.06, a 100% increase compared to the same period last year[6]. - Basic earnings per share decreased to ¥0.31 from ¥0.39, reflecting the decline in net profit[42]. - Deferred income increased by 62.73% to approximately CNY 53.28 million, reflecting an increase in government subsidies received[15]. - Deferred income increased to ¥53,284,159.24 from ¥32,744,803.82, indicating growth in future revenue recognition[36].